Med. praxi. 2024;21(5):315-319 | DOI: 10.36290/med.2024.048
Cardiovascular risk and combination therapy in practice of 2024
- Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace Fakultní nemocnice Olomouc
Cardiovascular diseases are the leading cause of mortality not only in the Czech Republic, but also in most countries of the world, with an ever-increasing prevalence. Arterial hypertension and dyslipidaemia are among the main risk factors for the development of CVD. Treatment is comprised of non-pharmacological measures, mainly changes in diet and increasing the amount of physical activity, as well as pharmacotherapy. Adherence to medication, which can be increased by the use of combination preparations, is a crucial factor in the success of treatment. Early intervention of risk factors will increase the length of life in good health, which is a more important indicator than life expectancy itself.
Keywords: artrial hypertension, dyslipidemia, cardiovascular prevention.
Received: October 17, 2024; Accepted: October 17, 2024; Published: December 2, 2024 Show citation
References
- Roth GA, Mensah GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action. J Am Coll Cardiol. 2020 Dec 22;76(25):2980-2981. doi: 10.1016/j.jacc.2020. 11. 021. PMID: 33309174.
Go to original source... - Prieto L, Sacristán JA. Problems and solutions in calculating quality‑adjusted life years (QALYs). Health Qual Life Outcomes. 2003 Dec 19;1:80. doi: 10.1186/1477-7525-1-80. PMID: 14687421; PMCID: PMC317370. Go to original source...
Go to PubMed... - Cífková R, et al. Prevalence hlavních rizikových faktorů kardiovaskulárních onemocnění v české populaci v letech 2015-2018. Studie Czech post‑MONICA. Cor Vasa. 2020;62(1):6-16. doi: 10.33678/cor.2020.010. Go to original source...
- Pinho R, Albini F, Nemcsik J, et al. European Society of Hypertension - general practitioners' program hypertension management: focus on general practice. Blood Press. 2023 Dec;32(1):2265132. doi: 10.1080/08037051.2023.2265132. Epub 2023 Oct 15. PMID: 37840300. Go to original source... Go to PubMed...
- Halcox JP, Banegas JR, Roy C, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross‑sectional observational study. BMC Cardiovasc Disord. 2017 Jun 17;17(1):160. doi: 10.1186/s12872-017-0591-5. PMID: 28623902; PMCID: PMC5473961. Go to original source... Go to PubMed...
- Visseren FLJ, Mach F, Smulders YM, et al; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. doi: 10.1093/eurheartj/ehac458. PMID: 34458905. Go to original source... Go to PubMed...
- Oude Wolcherink MJ, Behr CM, Pouwels XGLV, et al. Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review. Pharmacoeconomics. 2023 Oct;41(10):1183-1203. doi: 10.1007/s40273-023-01287-2. Epub 2023 Jun 16. PMID: 37328633; PMCID: PMC10492754. Go to original source... Go to PubMed...
- Cicero AFG, Fogacci F, Rizzoli E, et al. Long‑Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study. J Clin Med. 2021 Dec 17;10(24):5921. doi: 10.3390/jcm10245921. Erratum in: J Clin Med. 2022 Nov 30;11(23):7109. doi: 10.3390/jcm11237109. PMID: 34945217; PMCID: PMC8708144. Go to original source... Go to PubMed...